Yes, that is a fine theory. Add to that, maybe we "barely" missed Statistical Significance" on our Primary Endpoint, did achieve Clinical Significance, and also, achieved Statistical Significance on many or on most Secondary Endpoints. So the FDA is seriously considering supporting either EUA or full FDA approval for s/c and or for m/m.
The delay IMO, supports this or similar theories.